Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01916122 · ClinicalTrials.gov registry record · Early Phase 1
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
A Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 54
- Enrollment target
NCT01916122: Completed Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01916122 is a Early Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01916122, a Early Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
These are tumors which expresses estrogen receptors. Estrogen receptors are found within breast cancer cells and are an important marker of which medicines may best treat a breast cancer. This study is being performed to imaging the amount of estrogen receptors expressed in the tumor. A research agent named 16α-18F-fluoroestradiol (FES) finds estrogen receptors and binds to them. Then tumors with estrogen receptors can be imaged by a PET/CT scanner, a machine that can take pictures of where the FES is and how much FES is present. The results of this study may help researchers know whether FES can be used to monitor changes in estrogen receptors in tumors during treatment.
Interventions
- DRUG Fluorestradiol (FES)
- PROCEDURE PET/CT Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2013-08-01 |
| Est. Completion | 2024-04-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01916122
The ClinicalTrials.gov registry entry for NCT01916122 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluorestradiol (FES) is the first listed.
NCT01916122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01916122 about?
NCT01916122 is a clinical study titled "Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status". These are tumors which expresses estrogen receptors. Estrogen receptors are found within breast cancer cells and are an important marker of which medicines may best treat a breast cancer. This study is being performed to imaging the amount of estrogen receptors expressed in the tumor. A research age...
What is the current status of trial NCT01916122?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 54 participants. The study started on 2013-08-01. Estimated completion is 2024-04-03.
What interventions are being tested in trial NCT01916122?
The interventions under investigation include: Fluorestradiol (FES) (DRUG), PET/CT Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT01916122?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.